ACE and Mental deterioration: For example, several clinical studies suggest that administration of centrally acting ACE1 inhibitors to AD patients delays or prevents cognitive decline, improves cognition, and reduces the progression of disease neuropathology; thus, inhibiting ACE1 may have clinical benefits [30–37].